• SARS-Cov-2: Scientists hunt for its armour and its flaws

    Researchers have identified parts of the SARS-Cov-2 viral envelope most frequently targeted by antibodies. Located on the "nails", or viral proteins, they represent a potential target for vaccine development.

  • Spain: General Medicine better armed against Covid-19

    Private or public, Spanish general medicine proved its worth during the pandemic. No town was neglected. Family physicians know their patients well and accompany them. These were key strengths for identifying contact persons or following up on patients even from a distance.

  • Interview: Hi, I'm Annalisa

    We speak with Annalisa Malara, a resuscitation/reanimatology physician, who discovered the first case of COVID-19 in Italy in February 2020.

  • Germany: Endocrinology is at the forefront of COVID-19 research

    esanum spoke with Prof. Dr. Matthias Weber, media spokesman of the German Society of Endocrinology (German acronym: DGE), about the state of endocrinology in the COVID-19 crisis.

  • More insights on tumor mutation susceptibility found

    Scientists studied the molecular evolution of tumors after exposure to genetically damaging chemicals. They discovered that the chemical-induced defects in individual DNA building blocks are not repaired immediately but are passed on over several rounds of cell division.

  • New transport system for liver transplants

    A new project called "DeLiver" is currently developing a transport system for liver transplants. This system ensures optimal monitoring of organ functions with a flexible temperature regulation, nutrition and oxygen supply of the organ.

  • New research tackles the early detection of glaucoma

    The tissue hormone angiotensin II plays a role in the development of glaucoma. This finding could influence the diagnosis and therapy of glaucoma in the future.

  • Researchers classified colorectal cancer using infrared microscopes

    Researchers used infrared (IR) microscopes based on quantum cascade lasers (QCLs) to classify tissue samples of colorectal cancer. Using AI, it was possible to differentiate tumor types with great accuracy within 30 minutes allowing for a prognosis of the disease and the therapy choice.

  • Enabling the blind to see again?

    The Körber Prize for European Science 2020 will be awarded to Hungarian physician Botond Roska, who has revolutionized ophthalmology and the field of vision and retinal research. He has set himself the goal of restoring sight to the blind.

  • Positive prospects for dexamethasone in COVID-19 patients

    The University of Oxford announces that dexamethasone, a low-cost drug, reduces by up to one third the deaths of hospitalized COVID-19 patients with serious respiratory complications.

  • Aortic aneurysm: Improved outlook after surgery

    Some elderly and sick patients benefit from a minimally invasive treatment of an aortic aneurysm. However, open aortic artery operations continue to be a good (and in cases the only sensible) alternative.

  • Immunoncology: New findings in proteins tracing

    Researchers identified thousands of specific peptides on the surface of cells for the first time. These so-called cryptic peptides mark tumor cells to a significant extent and may provide a new starting point for cancer immunotherapies.

  • Reduced dose of certolizumab pegol in axSpA

    Outcomes of the C-OPTIMISE trial showed that a reduced maintenance dose of certolizumab pegol may be used in patients with axial spondyloarthritis (axSpA) treated with the drug for a year and who achieved sustained disease remission, regardless of subpopulation.

  • Composite endpoint CRESS for primary Sjogren’s syndrome

    A concept of the new ‘Composite of Relevant Endpoints for Sjogren’s Syndrome’ (CRESS) has been developed, which enables discriminating between abatacept and placebo response in patients with this condition.

  • Hydroxychloroquine not effective in patients with hand osteoarthritis

    Data from the first large, randomized, placebo-controlled trial OA TREAT, focusing on erosive hand osteoarthritis, showed that hydroxychloroquine was no more effective than placebo for changes in pain, function, and radiographic scores in the study period.

  • Recommendations for managing rheumatic and musculoskeletal diseases in the COVID-19 era

    These recommendations focus on prevention of COVID-19; managing patients in general; and managing patients who have been infected or have been in contact with a COVID-19 patient. They were simultaneously published in the Annals of the Rheumatic Diseases.

  • Secukinumab monotherapy as efficient as adalimumab

    Main trial data from the head-to-head EXCEED trial showed that, for patients who suffer from psoriatic arthritis and who are biologic-naïve, secukinumab monotherapy does not offer greater musculoskeletal benefits than adalimumab.

  • Rozibafusp alfa effective and tolerable in rheumatoid arthritis

    For the first time, safety and tolerability results were reported for multiple ascending doses of rozibafusp alfa in patients with RA. This showed greater improvement from baseline in Patient Global Assessments and Physician Global Assessments as well as a non-linear, target-mediated disposition.

  • TNF-α inhibitors improve BMD in ankylosing spondylitis patients

    Ankylosing spondylitis patients with longstanding disease achieved significant improvements in both lumbar spine and hip BMD during 8 years of tumor necrosis factor-alpha (TNF-α) blocking therapy- The effect in the lumbar spine was most pronounced and main improvements occurred during the first 4 years of treatment.

  • New nanoparticle promising future agent in rheumatoid arthritis

    A first-in-class therapeutic nanoparticle drug has been developed for the specific targeting of anti-citrullinated protein antibodies, which may be a promising agent for targeting antibodies to citrullinated proteins and peptides (ACPAs).

  • 60 |
  • 61 |
  • 62 |
  • 63 |
  • 64 |
  • 65 |
  • 66 |
  • 67 |
  • 68 |
  • 69 |
  • 70 |